USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: COLLAGEN MEDICAL, LLC
City: BELMONT
State: MA
Zip+4: 02478-3006
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: http://www.cmed.cc
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $604,656.00 3
SBIR Phase II $1,220,519.00 1

Award List:

Optimization of Efficacy and Safety Pharamacology of Fibrosis Imaging Agent CM-65

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Andrew F. Kolodziej – 617-643-0193
Award Amount: $189,822.00
Abstract:
DESCRIPTION (provided by applicant): Dramatic increases in the incidence of obesity, diabetes, and the metabolic syndrome are increasing the prevalence of chronic liver diseases. Liver fibrosis arising from an excessive deposition of type I collagen in theparenchyma, occurs in advanced stages of… More

CM-65, a Targeted Contrast Agent for Cardiac Magnetic Resonance Perfusion Imaging

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Valerie Humblet – 617-642-0585
Award Amount: $207,280.00
Abstract:
DESCRIPTION (provided by applicant): Assessment of myocardial perfusion is a gatekeeper diagnostic exam that has high sensitivity for identifying individuals with ischemic heart disease. Millions of perfusion studies are performed annually in the US usinga stress/rest paradigm with a radioactive… More

Optimization of Efficacy and Safety Pharamacology of Fibrosis Imaging Agent CM-65

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Andrew F. Kolodziej – 617-643-0193
Award Amount: $1,220,519.00
Abstract:
DESCRIPTION (provided by applicant): Dramatic increases in the incidence of obesity, diabetes, and the metabolic syndrome are increasing the prevalence of chronic liver diseases. Liver fibrosis arising from an excessive deposition of type I collagen in theparenchyma, occurs in advanced stages of… More

IGF::OT::IGF MR Contrast Agent to Quantify Myocardial Fibrosis - SBIR Topic 072 -

Award Year / Program / Phase: 2013 / SBIR / Phase I
Agency: HHS
Principal Investigator: Scott Turner – 617-970-3817
Award Amount: $207,554.00
Abstract:
Myocardial fibrosis is a crucial marker of adverse cardiac remodeling. Research suggests a strong correlationbetween the extent of myocardial fibrosis and adverse myocardial remodeling that occurs after ischemic injury orduring the progression of cardiomyopathies and heart failure. Diffuse… More